https://www.selleckchem.com/products/a-196.html s promising for its feasibility, impact, and a sustainable cost. © 2020 International Parkinson and Movement Disorder Society. Intra-articular triamcinolone acetonide is a widely used treatment for joint inflammation despite limited scientific evidence of its efficacy. To investigate if intra-articular triamcinolone acetonide has sustained anti-inflammatory effects using an equine model of repeated joint inflammation. Randomised controlled experimental study. For three consecutive cycles 2weeks apart, inflammation was induced in both middle carpal joints of eight horses by injecting 0.25ng lipopolysaccharide (LPS). After the first LPS injection only, treatment with 12mg triamcinolone acetonide (TA) followed in one randomly assigned joint, while the contralateral joint was treated with sterile saline (control). Clinical parameters (composite welfare scores, joint effusion, joint circumference) were recorded and synovial fluid samples were analysed for various biomarkers (total protein, WBCC; PGE ; CCL2; TNFα; MMP; GAGs; C2C; CPII) at fixed timepoints (post injection hours 0, 8, 24, 72 and 168). The effects of time and treatmuctions (Difference in means -51.65 RFU/s, 95% CI -92.4, -10.9, P<0.01). This experimental study cannot fully reflect natural joint disease. In this model, intra-articular TA seems to have some anti-inflammatory activity (demonstrated by reductions in TP, WBCC and general MMP activity) up to 2weeks post treatment but not at 4weeks. This anti-inflammatory effect appeared to outlast a shorter-lived, potentially detrimental effect illustrated by increased synovial GAG and PGE levels after the first induction. In this model, intra-articular TA seems to have some anti-inflammatory activity (demonstrated by reductions in TP, WBCC and general MMP activity) up to 2 weeks post treatment but not at 4 weeks. This anti-inflammatory effect appeared to outlast a shorter-lived, potentially detrimental effect illust